ES2094688B1 - Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. - Google Patents

Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Info

Publication number
ES2094688B1
ES2094688B1 ES09401784A ES9401784A ES2094688B1 ES 2094688 B1 ES2094688 B1 ES 2094688B1 ES 09401784 A ES09401784 A ES 09401784A ES 9401784 A ES9401784 A ES 9401784A ES 2094688 B1 ES2094688 B1 ES 2094688B1
Authority
ES
Spain
Prior art keywords
oil
water
procedure
percent
ophthalmic vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09401784A
Other languages
English (en)
Other versions
ES2094688A1 (es
Inventor
Dachs Anna Coll
Perdiguer Nuria Carreras
Valdivia Javier Galan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES09401784A priority Critical patent/ES2094688B1/es
Priority to AT95202053T priority patent/ATE243995T1/de
Priority to DE69531179T priority patent/DE69531179T2/de
Priority to EP95202053A priority patent/EP0696452B1/en
Priority to US08/509,746 priority patent/US5698219A/en
Priority to JP7200760A priority patent/JP2960867B2/ja
Publication of ES2094688A1 publication Critical patent/ES2094688A1/es
Application granted granted Critical
Publication of ES2094688B1 publication Critical patent/ES2094688B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Abstract

NANOEMULSION DEL TIPO DE ACEITE EN AGUA, UTIL COMO VEHICULO OFTALMICO Y PROCEDIMIENTO PARA SU PREPARACION. LA NANOEMULSION COMPRENDE 0,1-10 POR CIENTO (P/V) DE UN ACEITE; 0,1-10 POR CIENTO (P/V) DE UN TENSIOACTIVO NO IONICO; COMO MAXIMO 0,01 POR CIENTO (P/V) DE CLORURO DE BENZALCONIO; UN FARMACO O UN PRECURSOR O SUSTANCIA ACTIVA; Y OPCIONALMENTE, UNO O VARIOS DE LOS SIGUIENTES COMPONENTES: UN AGENTE ISOTONIZANTE, VISCOSIZANTE O ESTABILIZANTE, UN TAMPON Y/O UN ANTIOXIDANTE EN PROPORCIONES VARIABLES. EL PROCEDIMIENTO COMPRENDE: (A) PREPARAR UNA FASE ACUOSA CONTENIENDO, ENTRE OTROS, UN TENSIOACTIVO NO IONICO; (B) PREPARAR UNA FASE ORGANICA CONTENIENDO DISUELTOS UN ACEITE Y UNA SUSTANCIA ACTIVA EN UN DISOLVENTE ORGANICO MISCIBLE EN AGUA EN TODAS PROPORCIONES; (C) INCORPORAR LA FASE ORGANICA SOBRE LA ACUOSA BAZO MODERADA AGITACION; Y (D) EVAPORAR TOTALMENTE EL DISOLVENTE ORGANICO Y PARTE DEL AGUA HASTA EL VOLUMEN FINAL DESEADO. IMPORTANTES APLICACIONES COMO VEHICULO OFTALMICO EN PREPARADOS DESTINADOS AL TRATAMIENTO DE LOS TRASTORNOS Y ENFERMEDADES OCULARES.
ES09401784A 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. Expired - Fee Related ES2094688B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES09401784A ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
AT95202053T ATE243995T1 (de) 1994-08-08 1995-07-26 Nanoemulsion von dem öl-in-wasser typ, gebrauchbar als ein ophthalmischen vehikel und verfahren zur seiner herstellung
DE69531179T DE69531179T2 (de) 1994-08-08 1995-07-26 Nanoemulsion von dem Öl-in-Wasser Typ, gebrauchbar als ein ophthalmischen Vehikel und Verfahren zur seiner Herstellung
EP95202053A EP0696452B1 (en) 1994-08-08 1995-07-26 Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof
US08/509,746 US5698219A (en) 1994-08-08 1995-07-31 Nanoemulsion of the oil water type, useful as an ophthalmic vehicle and process for the preparation thereof
JP7200760A JP2960867B2 (ja) 1994-08-08 1995-08-07 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401784A ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Publications (2)

Publication Number Publication Date
ES2094688A1 ES2094688A1 (es) 1997-01-16
ES2094688B1 true ES2094688B1 (es) 1997-08-01

Family

ID=8287242

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09401784A Expired - Fee Related ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Country Status (6)

Country Link
US (1) US5698219A (es)
EP (1) EP0696452B1 (es)
JP (1) JP2960867B2 (es)
AT (1) ATE243995T1 (es)
DE (1) DE69531179T2 (es)
ES (1) ES2094688B1 (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
ES2118033B1 (es) * 1996-02-16 1999-07-01 Bial Ind Farmaceutica S A Formulacion farmaceutica antiinflamatoria.
CZ299116B6 (cs) 1997-11-19 2008-04-30 Intendis Gmbh Prípravek s kyselinou azelainovou
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
ES2341510T3 (es) * 1998-08-13 2010-06-21 Cima Labs Inc. Microemulsiones como formas farmaceuticas solidas para la administracion oral.
AU5405399A (en) * 1998-09-14 2000-04-03 Vesifact Ag Utilization of nanocells in final culture medium products
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
FR2787027B1 (fr) * 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) * 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) † 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) * 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
AU4808000A (en) 1999-04-28 2000-11-10 Situs Corporation Drug delivery system
US8232320B2 (en) * 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7655252B2 (en) * 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
FR2811564B1 (fr) * 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
ES2365223T3 (es) 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
WO2005051511A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation 有機化合物微粒子の製造方法
US8449867B2 (en) 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
AR051197A1 (es) * 2004-08-31 2006-12-27 Connetics Australia Pty Ltd Un procedimiento para obtener una microemulsion y sub-micron emulsion y composiciones
EP1809237B1 (en) * 2004-11-09 2008-12-31 Novagali Pharma SA Ophthalmic oil-in-water type emulsion with stable positive zeta potential
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
WO2007000842A1 (ja) * 2005-06-29 2007-01-04 Mitsubishi Chemical Corporation 粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
EP1951200A2 (en) * 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US20070281914A1 (en) 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
EP2420505A1 (en) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
ES2796116T3 (es) * 2006-12-21 2020-11-25 Santen Sas Procedimiento para la fabricación de emulsiones oftálmicas de tipo aceite en agua
US20080201330A1 (en) * 2007-02-16 2008-08-21 Microsoft Corporation Software repositories
US8145673B2 (en) * 2007-02-16 2012-03-27 Microsoft Corporation Easily queriable software repositories
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2009007409A2 (en) * 2007-07-09 2009-01-15 Novagali Pharma Sa Oil in water emulsion comprising nsaids and quaternary ammonium halides
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
ATE481087T1 (de) * 2007-07-09 2010-10-15 Novagali Pharma Sa Öl in wasser emulsionen enthaltend nsaid und quartär ammoniumhalogenide
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
US9649275B2 (en) * 2007-11-28 2017-05-16 Commonwealth Scientific And Industrial Research Organisation Nanoemulsions
WO2009071594A1 (en) * 2007-12-04 2009-06-11 Novagali Pharma Sa Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CA2719803A1 (en) * 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
CA2725523C (en) * 2008-05-28 2017-01-10 Alcon Research, Ltd. Self-preserved emulsions
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
ES2624622T3 (es) 2008-12-30 2017-07-17 Rigel Pharmaceuticals, Inc. Inhibidores de pirimidindiamina cinasa
PL2389372T3 (pl) 2009-01-23 2016-02-29 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
EP2393470B1 (en) 2009-02-06 2017-04-05 The Regents of The University of California Calcium-binding agents induce hair growth and/or nail growth
CN104523661A (zh) 2009-02-06 2015-04-22 南加利福尼亚大学 含有单萜的治疗组合物
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
WO2010144194A1 (en) 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
AU2010281404A1 (en) 2009-07-28 2012-02-09 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
US20110200644A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Ester Emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
PL2563771T3 (pl) 2010-04-24 2016-06-30 Viamet Pharmaceuticals Nc Inc Związki inhibitora metaloenzymu
CN103201280B (zh) 2010-07-28 2016-08-10 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP3173080B1 (en) 2010-08-27 2019-12-11 Neonc Technologies Inc. Pharmaceutical compositions comprising derivatives of perillyl alcohol
EP2632903A4 (en) 2010-10-28 2014-11-26 Viamet Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
EA024197B1 (ru) 2010-11-13 2016-08-31 Иннокрин Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
CA2820721C (en) * 2010-12-10 2017-07-11 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
BR112013015107B1 (pt) 2010-12-17 2022-03-22 Neonc Technologies Inc. Composição farmacêutica, uso de um álcool isoperílico ou um carbamato de álcool isoper ílico e processo para produzir um carbamato de álcool isoperílico
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
CN103608028A (zh) 2011-04-28 2014-02-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
US8809378B2 (en) 2011-06-19 2014-08-19 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CA2839691A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8883797B2 (en) 2011-06-23 2014-11-11 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP2788343B1 (en) 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
CN110075310A (zh) 2011-12-20 2019-08-02 维奥姆治疗有限公司 用于治疗真菌感染的局部油组合物
IN2014DN06792A (es) 2012-01-20 2015-05-22 Viamet Pharmaceuticals Inc
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
USRE49873E1 (en) 2012-03-19 2024-03-19 Buck Institute For Research On Aging APP specific bace inhibitors (ASBIs) and uses thereof
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2956443B1 (en) 2013-02-12 2019-09-25 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
KR101862448B1 (ko) * 2013-04-12 2018-05-29 바이옴 바이오사이언스 피브이티. 엘티디. 항균제의 조성물과 제제, 그 공정, 및 세균 감염을 치료하는 방법
JP2014028865A (ja) * 2013-11-11 2014-02-13 Santen Sas 眼科用水中油型乳剤を製造する方法
KR20160146669A (ko) * 2014-02-14 2016-12-21 징준 후앙 나노에멀젼 전달 시스템의 조성물
WO2015186040A1 (en) * 2014-06-02 2015-12-10 Sun Pharmaceutical Industries Limited Stable nanoemulsion composition
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
JP6674957B2 (ja) 2015-02-12 2020-04-01 ネオンク テクノロジーズ インク． ペリリルアルコール誘導体を含む医薬組成物
DK3331879T3 (da) 2015-08-04 2020-08-10 Rigel Pharmaceuticals Inc Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
MX2018008105A (es) 2015-12-30 2018-11-12 Vps 3 Inc Compuestos inhibidores de metaloenzima.
ES2940911T3 (es) 2016-06-27 2023-05-12 Rigel Pharmaceuticals Inc Compuestos de 2,4-diamino-pirimidina y su uso como inhibidores de IRAK4
EP3500344A4 (en) * 2016-08-19 2020-08-05 Akrivista, LLC METHOD OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
EP3532470B1 (en) 2016-10-26 2022-12-07 Rigel Pharmaceuticals, Inc. Oxazole derivatives for use as irak inhibitors and method for their preparation
WO2018081294A1 (en) 2016-10-26 2018-05-03 Rigel Pharmaceuticals, Inc. Pyrazole amide compounds as irak inhibitors
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
WO2018102412A1 (en) 2016-11-30 2018-06-07 Neonc Technologies, Inc. A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CA3049212A1 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US10590121B2 (en) 2017-06-29 2020-03-17 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
EP3668474A4 (en) 2017-08-18 2021-05-26 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
US11414450B1 (en) 2017-08-28 2022-08-16 Revagenix, Inc. Aminoglycosides and uses thereof
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2019157195A1 (en) 2018-02-08 2019-08-15 Neonc Technologies, Inc Methods of permeabilizing the blood brain barrier
US11673907B2 (en) 2018-04-03 2023-06-13 Revagenix, Inc. Modular synthesis of aminoglycosides
HUE063896T2 (hu) 2018-05-03 2024-02-28 Rigel Pharmaceuticals Inc RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása
ES2947446T3 (es) 2018-05-03 2023-08-09 Rigel Pharmaceuticals Inc Compuestos inhibidores de RIP1 y métodos para fabricar y usar los mismos
EP3843721A4 (en) * 2018-08-29 2022-10-12 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHODS OF USE
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
EP3914245A4 (en) 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. MTORC MODULATORS AND THEIR USES
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
GB201909358D0 (en) * 2019-06-28 2019-08-14 Smoukov Stoyan K Oil-in-water emulsion of nano-sized self-emulsified particulates
WO2021026451A1 (en) 2019-08-08 2021-02-11 Rigel Pharmaceuticals, Inc. Compounds and method for treating cytokine release syndrome
CA3147444A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
MX2022002292A (es) 2019-08-30 2022-06-02 Rigel Pharmaceuticals Inc Compuestos de pirazol, formulaciones de los mismos y un metodo para usar los compuestos y/o formulaciones.
EP4025568A1 (en) 2019-09-06 2022-07-13 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
KR20220079919A (ko) 2019-11-07 2022-06-14 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 억제 화합물
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
PL438501A1 (pl) * 2021-07-16 2023-01-23 Uniwersytet Medyczny Im.Piastów Śląskich We Wrocławiu Kompozycja w postaci nanoemulsji na bazie oleju roślinnego, kompozycja wielofazowa oraz sposób wytwarzania tych kompozycji
WO2023166488A1 (en) 2022-03-04 2023-09-07 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
US20230303555A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832721A (en) * 1956-07-23 1958-04-29 Merck & Co Inc Vitamin emulsions
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US5171566A (en) 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
JPS62270521A (ja) * 1986-05-16 1987-11-24 Green Cross Corp:The フルルビプロフエン眼投与製剤
IE873504L (en) * 1987-01-28 1988-07-28 Harvard College Stabilized ophthalmic compositions
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
WO1991018669A1 (en) * 1990-06-08 1991-12-12 Affinity Biotech, Inc. Process for preparing microemulsion
CA2052950A1 (en) * 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
IL98747A0 (en) 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
DE69328368T2 (de) * 1992-08-28 2000-08-10 Pharmos Corp Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge

Also Published As

Publication number Publication date
DE69531179T2 (de) 2004-04-15
ATE243995T1 (de) 2003-07-15
ES2094688A1 (es) 1997-01-16
EP0696452A1 (en) 1996-02-14
JPH0899867A (ja) 1996-04-16
EP0696452B1 (en) 2003-07-02
US5698219A (en) 1997-12-16
JP2960867B2 (ja) 1999-10-12
DE69531179D1 (de) 2003-08-07

Similar Documents

Publication Publication Date Title
ES2094688B1 (es) Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
ES2200008T3 (es) Formulacion espumable y espuma.
ES2443548T5 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
MX173607B (es) Antitranspirante cristalino y metodo para su preparacion
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
MX9306051A (es) Composicion desodorante en forma de barra de gel estable.
AR030093A1 (es) Sistema para la distribucion topica del gel
BR0108449A (pt) Formulações de pasta aperfeiçoada
ES2530774T3 (es) Método para producir partículas secas
DE69418468T2 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
PE63998A1 (es) Composiciones anti-fungosas
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
PT93638A (pt) Processo para a preparacao de uma composicao para a aplicacao topica do acido da vitamina a
ES2011232T3 (es) Composiciones farmaceuticas de piroxicam en soluciones acuosas y procedimiento para su preparacion.
ES2054690T3 (es) Uso farmaceutico de extractos de gramineas.
AR041936A1 (es) Formulacion micelar acuosa que comprende un primer agente activo seleccionado de bencimidazoles insolubles en agua, salicilanilidas y derivados activos o sales de los mismos en combinacion con un segundo agente activo seleccionado de lactonas macrociclicas o derivados activos o sales de las mismas y
PE20000158A1 (es) Formulacion insecticida acuosa para vertirse
KR940006575A (ko) 증가된 안내압 치료를 위한 안구 국소 투여용 약제학적 조성물
ES2208434T3 (es) Uso de la ubiquinona q10 para un tratamiento local y para la prevencion de las patologias oftamologicas posquirurgicas.
GT200000224A (es) Composicion para el tratamiento de tejidos dañados.
AR024903A1 (es) Empleo de uno o varios tensoactivos sacaridos, agente acuoso que contiene tensoactivos espesado y procedimiento para la elaboracion de un agente acuoso quecontiene tensoactivos espesado
FR2737135B1 (fr) Gels inverses a phase continue fluoree
AU3548901A (en) Veterinary compositions for the treatment of parasitic diseases
ES2155049T1 (es) Composicion biologicamente activa.
JP2006169222A (ja) 抗菌性組成物

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19970116

Kind code of ref document: A1

Effective date: 19970116

FD2A Announcement of lapse in spain

Effective date: 20180806